Marek Krogulec
Overview
Explore the profile of Marek Krogulec including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
350
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lebwohl M, Koo J, Jaworski J, Trefler J, Daniluk S, Dudek A, et al.
Adv Ther
. 2025 Feb;
42(3):1582-1599.
PMID: 39932677
Introduction: This study aimed to demonstrate the interchangeability of biosimilar CT-P17 and European Union reference adalimumab (EU-adalimumab) in a repeated-switch scenario. Methods: In this ongoing, randomized, double-blind, active-controlled, phase 3...
2.
Smolen J, Trefler J, Racewicz A, Jaworski J, Zielinska A, Krogulec M, et al.
RMD Open
. 2024 Oct;
10(4).
PMID: 39424404
Objectives: To demonstrate efficacy equivalence of CT-P47 and EU-approved reference tocilizumab (r-TCZ) in patients with rheumatoid arthritis (RA). Methods: This double-blind, phase III study randomised (1:1) patients to receive CT-P47...
3.
Daien C, Krogulec M, Gineste P, Steens J, Desroys du Roure L, Biguenet S, et al.
Ann Rheum Dis
. 2022 May;
81(8):1076-1084.
PMID: 35641124
Objective: This phase 2a randomised, double blind, placebo controlled, parallel group study evaluated the safety and efficacy of a first-in-class drug candidate ABX464 (obefazimod, 50 mg and 100 mg per...
4.
Furst D, Jaworski J, Wojciechowski R, Wiland P, Dudek A, Krogulec M, et al.
Rheumatology (Oxford)
. 2021 Jun;
61(4):1385-1395.
PMID: 34142111
Objective: To compare the safety and efficacy of switching from reference adalimumab to adalimumab biosimilar CT-P17 with continuing reference adalimumab/CT-P17 in active RA. Methods: This double-blind, phase III study randomized...
5.
Kay J, Jaworski J, Wojciechowski R, Wiland P, Dudek A, Krogulec M, et al.
Arthritis Res Ther
. 2021 Feb;
23(1):51.
PMID: 33546755
Background: To demonstrate equivalent efficacy of the proposed high-concentration (100 mg/ml), citrate-free adalimumab biosimilar CT-P17 to European Union-approved adalimumab (EU-adalimumab) in subjects with active rheumatoid arthritis (RA). Methods: This randomized,...
6.
Suh C, Yoo D, Kasay A, Chalouhi El-Khouri E, Cons Molina F, Shesternya P, et al.
BioDrugs
. 2019 Feb;
33(1):79-91.
PMID: 30719632
Objective: The aim of this study was to investigate long-term clinical outcomes of extended treatment with CT-P10, a rituximab biosimilar, compared with rituximab reference products sourced from the USA and...
7.
Genovese M, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, et al.
N Engl J Med
. 2016 Mar;
374(13):1243-52.
PMID: 27028914
Background: In phase 2 studies, baricitinib, an oral Janus kinase 1 and 2 inhibitor, reduced disease activity in patients with rheumatoid arthritis who had not previously received treatment with biologic...
8.
Emery P, Hammoudeh M, FitzGerald O, Combe B, Martin-Mola E, Buch M, et al.
N Engl J Med
. 2014 Nov;
371(19):1781-92.
PMID: 25372086
Background: We assessed the effects of reduction and withdrawal of treatment in patients with rheumatoid arthritis who had a remission while receiving etanercept-plus-methotrexate therapy. Methods: Patients with early active disease...